Literature DB >> 2744885

Ganglioside GD3 shedding by human malignant melanoma cells.

H Bernhard1, K H Meyer zum Büschenfelde, W G Dippold.   

Abstract

Gangliosides appear to be important target molecules for immunological effector mechanisms on neuro-ectodermal tumors. Therefore in vitro studies were performed to examine whether ganglioside GD3, which is highly expressed on the cell surface of cultured human melanoma cells, is being shed into the culture medium. Measurable quantities of gangliosides GM3 and in particular GD3 were shed by the melanoma cells we have tested as detected on thin-layer chromatograms (TLC) stained with orcinol. Ganglioside GD3 was also evidenced by immunostaining with anti-GD3 MAb and by ELISA. The concentration of GD3 in the supernatant of human melanoma cells depended on the ganglioside pattern of the cell line. Cells containing high levels of GD3 shed large amounts, cells with low levels shed no detectable GD3. Ganglioside GD3 was detectable in sera, but no major quantitative differences were observed in sera of patients with GD3-positive tumors and normal controls. This points to a local accumulation of ganglioside GD3 at the tumor site.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2744885     DOI: 10.1002/ijc.2910440127

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  13 in total

1.  Melanoma cells constitutively release an anchor-positive soluble form of protectin (sCD59) that retains functional activities in homologous complement-mediated cytotoxicity.

Authors:  L I Brasoveanu; E Fonsatti; A Visintin; M Pavlovic; I Cattarossi; F Colizzi; A Gasparollo; S Coral; V Horejsi; M Altomonte; M Maio
Journal:  J Clin Invest       Date:  1997-09-01       Impact factor: 14.808

2.  3'-Azidothymidine significantly alters glycosphingolipid synthesis in melanoma cells and decreases the shedding of gangliosides.

Authors:  R Steet; M Alizadeh; P Melançon; R D Kuchta
Journal:  Glycoconj J       Date:  1999-03       Impact factor: 2.916

3.  Ganglioside-exposed dendritic cells inhibit T-cell effector function by promoting regulatory cell activity.

Authors:  Alessandra Jales; Rustom Falahati; Elisabeth Mari; Erik J Stemmy; Weiping Shen; Cathy Southammakosane; Dallen Herzog; Stephan Ladisch; David Leitenberg
Journal:  Immunology       Date:  2010-09-28       Impact factor: 7.397

4.  Ganglioside GD3 shedding by human gliomas.

Authors:  O Nakamura; M Iwamori; M Matsutani; K Takakura
Journal:  Acta Neurochir (Wien)       Date:  1991       Impact factor: 2.216

5.  Evaluation of the efficiency of an assay procedure for gangliosides in human serum.

Authors:  E Negroni; V Chigorno; G Tettamanti; S Sonnino
Journal:  Glycoconj J       Date:  1996-06       Impact factor: 2.916

6.  Targeting of T lymphocytes to melanoma cells through chimeric anti-GD3 immunoglobulin T-cell receptors.

Authors:  C O Yun; K F Nolan; E J Beecham; R A Reisfeld; R P Junghans
Journal:  Neoplasia       Date:  2000 Sep-Oct       Impact factor: 5.715

7.  Gangliosides inhibit the development from monocytes to dendritic cells.

Authors:  M Wölfl; W Y Batten; C Posovszky; H Bernhard; F Berthold
Journal:  Clin Exp Immunol       Date:  2002-12       Impact factor: 4.330

8.  Ceramide structure predicts tumor ganglioside immunosuppressive activity.

Authors:  S Ladisch; R Li; E Olson
Journal:  Proc Natl Acad Sci U S A       Date:  1994-03-01       Impact factor: 11.205

9.  Tumor gangliosides accelerate murine tumor angiogenesis.

Authors:  Yihui Liu; Assefa Wondimu; Su Yan; Daniel Bobb; Stephan Ladisch
Journal:  Angiogenesis       Date:  2013-10-29       Impact factor: 9.596

10.  Different mechanisms are involved in apoptosis induced by melanoma gangliosides on human monocyte-derived dendritic cells.

Authors:  Karim Bennaceur; Iuliana Popa; Jessica Alice Chapman; Camille Migdal; Josette Péguet-Navarro; Jean-Louis Touraine; Jacques Portoukalian
Journal:  Glycobiology       Date:  2009-02-24       Impact factor: 4.313

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.